Scientists evaluated the effectiveness and safety of reduced-dose cyclophosphamide, 20 mg/kg for 13 patients in matched sibling donor hematopoietic stem cell transplantation (HSCT) cohort and 25 mg/kg for 22 patients in haplo-HSCT cohort, on days +3, +4 combined with cotransplantation of peripheral blood stem cells and human umbilical cord-derived MSCs for severe aplastic anemia (SAA).
[Scientific Reports]
Zu, Y., Zhou, J., Fu, Y., Fang, B., Liu, X., Zhang, Y., Yu, F., Zuo, W., Zhou, H., Gui, R., Li, Z., Liu, Y., Zhao, H., Zhang, C., & Song, Y. (2021). Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA. Scientific Reports, 11(1), 253. https://doi.org/10.1038/s41598-020-80531-7 Cite
0